Loading...

Media
- Media
- Press Releases
- Media Statements
- Media Library
Investors
< Back

Investors

Financial Results

Corporate News

Financial Calendar

Investor Events

Reports and Accounts

Regulated Information
Combined Shareholders’ Meeting 2024 (pre announcement page launch)
Partnering
Careers
- Careers
- Careers
- Working at Ipsen
- Culture

Loading...
English EN Français FR EN
- EnglishEN
- FrançaisFR
Global
< Back
- Global EN FR
- Annual Report EN FR
United States

Brazil

Canada EN

Canada FR

Mexico

Australia

China

Singapore

South Korea

Japan

Belgium

Ukraine

UK

Germany

France

Nordics

Greece

Italy

Netherlands

Spain

Poland

Russia

Slovakia

Czech Republic

Austria

Switzerland

Middle East

Home
Company
- Company
- Company
- Leadership
- History
- Fondation Ipsen
Science
- Science
- Oncology
- Rare Disease
- Neuroscience
- Products
- R&D
- Pipeline
- Clinical Trials
Responsibility
- Responsibility
- Responsibility
- Environment
- Patients
- People
- Governance
Patients
Stories

Home
Stories
Acquisition/Merger story

Epizyme welcome to Ipsen

Back

Post navigation

Epizyme welcome to Ipsen

Hear what CEO David Loew has to say about the official close of its acquisition of Epizyme.

Epizyme welcome to Ipsen

- 12 August 2022 - 1 mins read

Epizyme welcome to Ipsen

Hear what CEO David Loew has to say about the official close of its acquisition of Epizyme.

Post navigation

Share this on social media

IPN price

€113.10

€1.20 (1.07%)

Media
Investors
Partnering
Careers

Company
Responsibility
Patients
Stories

Annual Report
Contact us

Terms and Conditions
Cookie Policy
Global Privacy Policy

Copyright © Ipsen Pharma. All rights reserved - 2023

You are now leaving the Ipsen group website.To continue, please click on Continue?